These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 19152171)

  • 21. Hairy Cell Leukemia: Retrospective Analysis of Demographic Data and Outcome of 203 Patients from 12 Medical Centers in Israel.
    Inbar M; Herishanu Y; Goldschmidt N; Bairey O; Yuklea M; Shvidel L; Fineman R; Aviv A; Ruchlemer R; Braester A; Najib D; Rouvio O; Shaulov A; Greenbaum U; Polliack A; Tadmor T
    Anticancer Res; 2018 Nov; 38(11):6423-6429. PubMed ID: 30396967
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 2-Chlorodeoxyadenosine: treatment of hairy cell leukemia, chronic lymphocytic leukemia, and lymphocytic lymphoma.
    Piro LD
    Semin Hematol; 1993 Oct; 30(4 Suppl 6):28-30. PubMed ID: 7908756
    [No Abstract]   [Full Text] [Related]  

  • 23. [Complete remission in a patient with hairy cell leukemia after treatment with 2-chlorodeoxyadenosine].
    Komarnicki M; Kaźmierczak M
    Acta Haematol Pol; 1993; 24(1):77-81. PubMed ID: 8098177
    [No Abstract]   [Full Text] [Related]  

  • 24. New rearrangement pattern after treatment of hairy-cell leukemia with 2-chlorodeoxyadenosine.
    Schirmer M; Haun M; Grünewald K; Geisen F; Hilbe W; Thaler J; Konwalinka G
    Acta Haematol; 2000; 103(2):109-11. PubMed ID: 10838455
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful pregnancy after cladribine therapy for hairy cell leukemia.
    Orlowski RZ
    Leuk Lymphoma; 2004 Jan; 45(1):187-8. PubMed ID: 15061219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cladribine (2-chlorodeoxyadenosine) therapy in hairy cell leukemia variant. A report of three cases.
    Palomera L; Domingo JM; Sola C; Azaceta G; Calvo MT; Gutierrez M
    Haematologica; 2002 Jan; 87(1):107-8. PubMed ID: 11801472
    [No Abstract]   [Full Text] [Related]  

  • 27. Randomized trial of daily versus weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia: a multicenter phase III trial (SAKK 32/98).
    Zenhäusern R; Schmitz SF; Solenthaler M; Heim D; Meyer-Monard S; Hess U; Leoncini L; Bargetzi M; Rufener B; Tobler A
    Leuk Lymphoma; 2009 Sep; 50(9):1501-11. PubMed ID: 19672771
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of cladribine at Scripps for hairy cell leukemia and current results.
    Torrey ML; Sigal DS; Saven A
    Leuk Lymphoma; 2011 Jun; 52 Suppl 2():29-33. PubMed ID: 21504293
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 2-CdA in the treatment of hairy cell leukemia: a review of long-term follow-up.
    Gidron A; Tallman MS
    Leuk Lymphoma; 2006 Nov; 47(11):2301-7. PubMed ID: 17107901
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hairy Cell Leukemia and cutaneous involvement.
    Ergene U; Ozbalcı D; Işisağ A
    Transfus Apher Sci; 2012 Apr; 46(2):231-2. PubMed ID: 22370038
    [No Abstract]   [Full Text] [Related]  

  • 31. [Failure of treatment with 2-chlorodeoxyadenosine in the course of hairy cell leukemia associated with malignant histiocytosis].
    Jullien V; Peyrade F; Taillan B; Perrin C; Sanderson F; Guzman-Granier E; Michiels JF; Dujardin P
    Rev Med Interne; 1999 Mar; 20(3):287-8. PubMed ID: 10216890
    [No Abstract]   [Full Text] [Related]  

  • 32. [Hairy cell leukemia treated with cladribine].
    Ghanima W; Heldal D; Tjønnfjord GE
    Tidsskr Nor Laegeforen; 2002 Apr; 122(11):1094-7. PubMed ID: 12043051
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Hairy cell leukemia and its treatment with 2-chlorodeoxyadenosine (2-CdA)].
    Pawelski S
    Acta Haematol Pol; 1995; 26(2):139-43. PubMed ID: 7653218
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hairy cell leukemia: epidemiology, pharmacokinetics of cladribine, and long-term follow-up of subcutaneous therapy.
    Juliusson G; Samuelsson H;
    Leuk Lymphoma; 2011 Jun; 52 Suppl 2():46-9. PubMed ID: 21599605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hairy-cell leukaemia as a model for drug development.
    Carson DA; Leoni LM
    Best Pract Res Clin Haematol; 2003 Mar; 16(1):83-9. PubMed ID: 12670467
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Criteria for use of cladribine in adults.
    Fedak MN
    Am J Hosp Pharm; 1994 Sep; 51(17):2185-6. PubMed ID: 7985700
    [No Abstract]   [Full Text] [Related]  

  • 37. 2-chlorodeoxyadenosine-associated transient acantholytic dermatosis in hairy cell leukemia patients.
    Cohen PR; Kurzrock R
    Am J Dermatopathol; 1999 Feb; 21(1):106-8. PubMed ID: 10027536
    [No Abstract]   [Full Text] [Related]  

  • 38. [Treatment of hairy cell leukemia with cladribine].
    Aurer I; Mitrović Z; Kovacević-Metelko J; Radman I; Basić-Kinda S; Gjadrov-Kuvezdić K; Jakić-Razumović J; Dubravcić K; Ries S; Nola M; Zupancic-Salek S; Labar B
    Lijec Vjesn; 2007; 129(3-4):80-3. PubMed ID: 17557550
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Excellent outcome of hairy cell leukaemia with extensive mesenteric infiltration following cladribine therapy.
    Juárez Salcedo LM; Sandoval-Sus J; Zhang L; Klippenstein D; Chavez JC
    Br J Haematol; 2016 Sep; 174(5):659. PubMed ID: 27391097
    [No Abstract]   [Full Text] [Related]  

  • 40. Minimal residual disease in hairy-cell leukemia after treatment with 2-chlorodeoxyadenosine.
    Konwalinka G; Schirmer M; Hilbe W; Fend F; Geisen F; Knoblechner A; Petzer A; Thaler J
    Blood Cells Mol Dis; 1995; 21(2):142-51. PubMed ID: 8846043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.